Who owns the IP
The organizations most actively patenting around this compound, ranked by referenced patent volume.
| # | Assignee | Patents |
|---|---|---|
| 1 | Emory University | 20 |
| 2 | BioNTech SE | 14 |
| 3 | United States Department of Health and Human Services | 9 |
| 4 | Verinos Operations GmbH | 7 |
| 5 | Astellas Pharma Inc | 6 |
| 6 | Centre National de la Recherche Scientifique | 5 |
| 7 | Beijing Tongren Hospital | 4 |
| 8 | Boehringer Ingelheim International GmbH | 4 |
| 9 | Universiteit Maastricht | 4 |
| 10 | Cincinnati Children's Hospital Medical Center | 3 |
Explore the full landscape
This preview shows the leading assignees. Cypris reveals the full ownership landscape - every filing entity, filing trends, and portfolio momentum.
Visit CyprisWhere innovation is concentrated
Patent classifications ranked by volume reveal the technical domains with the most active filing.
| # | Code | Area | Patents |
|---|---|---|---|
| 1 | A61K | Medicinal preparations | 119 |
| 2 | A61P | Therapeutic activity (drug indications) | 113 |
| 3 | C07K | Peptides | 35 |
| 4 | C12N | Microorganisms, enzymes | 31 |
| 5 | C07D | Heterocyclic compounds | 24 |
| 6 | G01N | Investigating / analysing materials | 19 |
| 7 | C12Q | Measuring/testing involving enzymes | 16 |
| 8 | A61Q | Cosmetics, personal care | 12 |
| 9 | Y02A | Climate change adaptation | 12 |
| 10 | C12Y | Enzyme nomenclature (EC numbers) | 10 |
AI mapped opportunity space
This preview shows where patent activity concentrates. Cypris maps the full classification landscape to surface technical whitespace and IP headroom.
See Cypris in actionWhere research is gaining momentum
Research themes ranked by publication activity show where scientific interest is accelerating around this compound.
| # | Research topic | Papers |
|---|---|---|
| 1 | Neuroscience of respiration and sleep | 1 |
| 2 | Neutrophil, Myeloperoxidase and Oxidative Mechanisms | 1 |
Who's driving the science
The most-published authors working with this compound, alongside their primary affiliations.
| # | Author | Affiliation | Papers |
|---|---|---|---|
| 1 | Bin Liu | Central South University | 3 |
| 2 | Jun Peng | Central South University | 3 |
| 3 | Patricia I. Oteiza | University of California, Davis | 3 |
| 4 | Adriana V. Treuer | University of Talca | 2 |
| 5 | Daniel R. González | University of Talca | 2 |
| 6 | Daniel Simões | Universidade de São Paulo | 1 |
| 7 | Galina Yu. Mironova | Koltzov Institute of Developmental Biology | 2 |
| 8 | Gang Dai | The First Affiliated Hospital, Sun Yat-sen University | 2 |
| 9 | Harald Schmidt | Monash University | 2 |
| 10 | Jianwen Chen | Sun Yat-sen University | 2 |
Research leaders
This preview lists the top authors. Cypris surfaces the full researcher landscape, their affiliations, and how scientific influence is shifting.
See Cypris in actionThe literature that defines it
The most-cited papers anchoring the scientific record for this compound.
| Title | Year | Cited by | Topic |
|---|---|---|---|
| RETRACTED ARTICLE: NOX4-dependent fatty acid oxidation promotes NLRP3 inflammasome activation in macrophages | 2016 | 291 | Inflammasome and immune disorders |
| Novel Nox inhibitor VAS2870 attenuates PDGF-dependent smooth muscle cell chemotaxis, but not proliferation☆ | 2006 | 253 | Nitric Oxide and Endothelin Effects |
| NOX4-dependent neuronal autotoxicity and BBB breakdown explain the superior sensitivity of the brain to ischemic damage | 2017 | 157 | Nitric Oxide and Endothelin Effects |
| Glutathione Peroxidase-1 Deficiency Potentiates Dysregulatory Modifications of Endothelial Nitric Oxide Synthase and Vascular Dysfunction in Aging | 2013 | 134 | Nitric Oxide and Endothelin Effects |
| Novel Nox inhibitor of oxLDL-induced reactive oxygen species formation in human endothelial cells | 2006 | 124 | Nitric Oxide and Endothelin Effects |
Frequently asked questions
Common questions about this compound's patent and research landscape, answered from the underlying data.
What is the molecular composition of VAS2870?
Which organizations hold the most patents for VAS2870?
What is the primary biological mechanism of action described in VAS2870 research?
What are the dominant patent classification areas for VAS2870?
What is the recent patent activity trend for VAS2870?